🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

An Observational Study of Local Relapse After High Grade Osteosarcoma

Recruitingn/aAges any - anyAllIstituto Ortopedico Rizzoli
NCT06017518 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

multicenter retrospective and prospective study in patients with high-grade osteosarcoma

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients who experienced LR as first event of recurrence after treatment for localized high-grade osteosarcoma of bone, including cases with synchronous lung metastases * Adequate patient compliance to follow-up visits * Written informed consent prior to any study-specific analysis and/or data collection * No age limits Exclusion Criteria: * Cases of LR demonstrated after \> 3 months after metastatic disease * Impossibility to ensure adequate compliance
💊

What it tests

  • Not listed
📍

Where

2 sites
IRCCS Istituto Ortopedico Rizzoli
Bologna, Italy
Azienda Ospedaliero-Universitaria Pisana
Pisa, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy